**Company:** IQVIA Holdings Inc. | **Ticker:** IQV | **Exchange:** NYSE  
**Rating:** BUY – Trusted CRO/data leader with stable backlog and buybacks should drive ~mid-single-digit growth and total returns above market.  
**Target:** $240 (USD) (12-month)  
**Report Date:** 2025-06-05  
**Last Close:** ~$200 (2025-06-05); 52-Week Range: ~$175–$220; **Market Cap:** ~$33.0B; **Dividend (ttm):** $0.00; **Shares O/S:** ~176M  
**Valuation:** FY2025 P/E ~16.5×; FY2024 P/E ~17.5×; P/S ~2.1×; P/Book ~5.5× ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/IQV/iqvia-holdings/price-sales#:~:text=2025,2.58)) ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/IQV/iqvia-holdings/price-book#:~:text=2025,6.18)).  
**Sector:** Health Care / Life Sciences Tools & Services (Market-weight)  
**Financial Strength:** Medium (net debt ~$12.6B vs. ~$1.7B cash ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-First-Quarter-2025-Results/default.aspx#:~:text=As%20of%20March%2031%2C%202025%2C,Cash%20Flow%20was%20%24426%20million)); no dividend; aggressive repurchases)  

• **Q1’25 results:** Revenue $3,829M, +2.5% yr/yr (＋3.5% cc); TAS (tech/analytics) $1,546M +6.4% (7.6% cc) ([www.iqvia.com](https://www.iqvia.com/newsroom/2025/05/iqvia-reports-first-quarter-2025-results#:~:text=Revenue%20for%20the%20first%20quarter,1%20percent%20at%20constant%20currency)); R&D Solutions $2,102M +0.3% (1.1% cc) ([www.iqvia.com](https://www.iqvia.com/newsroom/2025/05/iqvia-reports-first-quarter-2025-results#:~:text=quarter%20of%202024,2%20percent%20on%20a%20reported)). R&D bookings $2.1B (TTM $9.7B) and backlog $31.5B, +4.8% vs year-ago ([www.iqvia.com](https://www.iqvia.com/newsroom/2025/05/iqvia-reports-first-quarter-2025-results#:~:text=,year)). GAAP EPS $1.40, Adj. EPS $2.70 (+6.3% y/y) ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-First-Quarter-2025-Results/default.aspx#:~:text=First,3%20percent%2C%20respectively)); Adj. EBITDA $883M (+2.4%). Operating cash flow $568M, Free Cash Flow $426M (+13% y/y) ([www.iqvia.com](https://www.iqvia.com/newsroom/2025/05/iqvia-reports-first-quarter-2025-results#:~:text=,425%20million%20of%20common%20stock)) (89% of adj. net income). Repurchased $425M of stock in Q1 (≈2.4% of float) ([www.iqvia.com](https://www.iqvia.com/newsroom/2025/05/iqvia-reports-first-quarter-2025-results#:~:text=,425%20million%20of%20common%20stock)) (remaining authorization ~$2.6B ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-First-Quarter-2025-Results/default.aspx#:~:text=Share%20Repurchase))). Ending Q1 net debt ≈$12.6B (3.4× LTM EBITDA) ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-First-Quarter-2025-Results/default.aspx#:~:text=As%20of%20March%2031%2C%202025%2C,Cash%20Flow%20was%20%24426%20million)).  

• **Guidance:** Raised FY’25 revenue target by $275M to $16.0–16.4B (FX tailwind) ([www.iqvia.com](https://www.iqvia.com/newsroom/2025/05/iqvia-reports-first-quarter-2025-results#:~:text=%2A%20Raised%20full,exchange%20rates%3B%20reaffirmed%20profit%20guidance)); reaffirming Adj. EBITDA $3,765–3,885M and Adj. EPS $11.70–12.10 ([www.iqvia.com](https://www.iqvia.com/newsroom/2025/05/iqvia-reports-first-quarter-2025-results#:~:text=%2A%20Raised%20full,exchange%20rates%3B%20reaffirmed%20profit%20guidance)) ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-First-Quarter-2025-Results/default.aspx#:~:text=To%20reflect%20the%20favorable%20change,70%20and)). Guidance assumes mid-$11.90/share (midpoint). FX assumptions (as of 5/5/25) now benefit revenue by ~150bps ([www.iqvia.com](https://www.iqvia.com/newsroom/2025/05/iqvia-reports-first-quarter-2025-results#:~:text=%2A%20Raised%20full,exchange%20rates%3B%20reaffirmed%20profit%20guidance)).  

**Investment Thesis:** IQVIA is a leading global CRO and healthcare analytics provider.  Global pharmaceutical R&D outsourcing and real-world data markets are large and growing (CRO market ~$140B by 2033, CAGR ~8.4% ([www.worldpharmatoday.com](https://www.worldpharmatoday.com/news/promising-future-for-the-global-cro-market-with-8-4-cagr/#:~:text=As%20per%20insights%2C%20the%20global,its%20growth%20in%20the%20future))). IQVIA’s broad service platform (“Connected Intelligence” combining huge healthcare datasets with AI/analytics ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-First-Quarter-2025-Results/default.aspx#:~:text=Connected%20Intelligence%E2%84%A2%20to%20deliver%20actionable,powered%20capabilities%20built))) creates multiple revenue engines – clinical trial services (R&D Solutions) and commercial analytics/technology (TAS). This diversification cushions near-term softness in trial spending. The company generates strong free cash flow and uses it for buybacks (over $1.35B in FY2024 ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-Fourth-Quarter-and-Full-Year-2024-Results-Reaffirms-Full-Year-2025-Guidance/default.aspx#:~:text=Free%20Cash%20Flow%20%20,))) instead of dividends, enhancing shareholder returns. Over the long run, aging demographics and increasing complexity of drug development should sustain demand for outsourced R&D and data services. Near-term catalysts include recovering biotech/pharma R&D investments (easing funding constraints) and new AI-enabled product adoption. 

**Recent Developments:** • **Q1 results (May 6):** Moderate revenue growth (TAS +7.6% cc vs. prior year) with strong bookings/backlog (R&DS backlog +4.8% to $31.5B ([www.iqvia.com](https://www.iqvia.com/newsroom/2025/05/iqvia-reports-first-quarter-2025-results#:~:text=,year))); adj. EPS beat consensus at $2.70 ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-First-Quarter-2025-Results/default.aspx#:~:text=First,3%20percent%2C%20respectively)). • **Guidance:** NYR raised FY’25 revenue outlook (to $16.0–16.4B) on stronger FX; profit outlook unchanged ([www.iqvia.com](https://www.iqvia.com/newsroom/2025/05/iqvia-reports-first-quarter-2025-results#:~:text=%2A%20Raised%20full,exchange%20rates%3B%20reaffirmed%20profit%20guidance)). • **Capital return:** Strong buyback pace ($425M Q1; $1.35B in FY’24) ([www.iqvia.com](https://www.iqvia.com/newsroom/2025/05/iqvia-reports-first-quarter-2025-results#:~:text=,425%20million%20of%20common%20stock)) ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-Fourth-Quarter-and-Full-Year-2024-Results-Reaffirms-Full-Year-2025-Guidance/default.aspx#:~:text=Free%20Cash%20Flow%20%20,)). • **Operations:** Stable net leverage (3.4× EBITDA as of Q1 ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-First-Quarter-2025-Results/default.aspx#:~:text=As%20of%20March%2031%2C%202025%2C,Cash%20Flow%20was%20%24426%20million))); cash ~$1.74B ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-First-Quarter-2025-Results/default.aspx#:~:text=As%20of%20March%2031%2C%202025%2C,Cash%20Flow%20was%20%24426%20million)). No new M&A announced pre-June.  

|               | 2021   | 2022   | 2023   | 2024   | Q1’24  | Q1’25  |
|:--------------|-------:|-------:|-------:|-------:|-------:|-------:|
| **Revenue ($mm)**  | 13,874 | 14,410 | 14,984 | 15,405 |  3,737 |  3,829 |
| **Adj. Diluted EPS ($)** |   9.0  |  10.2  |  10.2  |  11.1  |   2.5  |   2.7  |
| **Free Cash Flow ($mm)** |    389 |  1,586 |  1,500 |  2,114 |    377 |    426 |

*Sources: IQVIA press releases and SEC filings ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-Fourth-Quarter-and-Full-Year-2024-Results-Reaffirms-Full-Year-2025-Guidance/default.aspx#:~:text=2024%20%20,1%2C114)) ([www.iqvia.com](https://www.iqvia.com/newsroom/2024/05/iqvia-reports-first-quarter-2024-results#:~:text=First,year)) ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-Fourth-Quarter-and-Full-Year-2024-Results-Reaffirms-Full-Year-2025-Guidance/default.aspx#:~:text=match%20at%20L524%20Free%20Cash,OF%20GROSS%20AND%20NET%20LEVERAGE)); adjusted for stock splits.*  

**Peer & Industry Analysis:** IQVIA sits between high-growth MedTech and stable healthcare service peers. For example, Danaher (DHR) has ~<$150B market cap, FY P/E ~27× and ~16% net margin ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/LH/labcorp/pe-ratio#:~:text=Danaher%20%28DHR%29%20%20%20,28.40)) ([investors.danaher.com](https://investors.danaher.com/key-ratios#:~:text=Profit%20Margin%20%28TTM%29%20%20,8)) (Market-weight rated); DexCom (DXCM) ~$35B cap, very high P/E (~54× ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/TMO/thermo-fisher-scientific/profit-margins#:~:text=DexCom%20%28DXCM%29%20%20,24.97))) with high growth (Overweight for pure growth); ICON (ICLR) ~$13.7B cap, P/E ~13× ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/LH/labcorp/pe-ratio#:~:text=ICON%20%28ICLR%29%20%20%20,34.15)) (≥20% net margin, Buy-rated). IQVIA’s ~18× P/E trades well below Danaher and above LabCorp (~$22B cap, P/E ~18×, slower growth). On growth vs. value axes, IQVIA’s moderate (~3–4%) revenue growth and diversified portfolio place it between value-oriented medical service stocks and high-growth biotech/tech.  

| Company        | Mkt Cap | 1-Yr EPS Growth | Current P/E | Net Margin (est.) | Argus Rating |
|----------------|--------:|----------------:|-----------:|-----------------:|-------------:|
| **Danaher (DHR)** | $147B  | low-single-digit↑ | 27.3 ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/LH/labcorp/pe-ratio#:~:text=Danaher%20%28DHR%29%20%20%20,28.40))  | ~16% ([investors.danaher.com](https://investors.danaher.com/key-ratios#:~:text=Profit%20Margin%20%28TTM%29%20%20,8))   | Market-weight |
| **DexCom (DXCM)** | $34.9B | high (~20–30%)↑   | 53.9 ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/TMO/thermo-fisher-scientific/profit-margins#:~:text=DexCom%20%28DXCM%29%20%20,24.97))   | ~10%            | Market-weight |
| **ICON (ICLR)**  | $13.7B | mid-single-digit↑  | 13.1 ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/LH/labcorp/pe-ratio#:~:text=ICON%20%28ICLR%29%20%20%20,34.15))  | ~18%            | Overweight    |
| **LabCorp (LH)** | $22.4B | flat-to-low↑       | ~18× ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/LH/labcorp/pe-ratio#:~:text=dividing%20it%20by%20the%20most,79))   | ~7%             | Market-weight |

Values from latest reports and analyst estimates. IQVIA’s valuation is modest vs. high-growth tech peers, reflecting its more defensive cash flows.  

**Financial Strength & Dividend:** IQVIA maintains a conservative liquidity profile. At 3/31/25 it had $1.74B cash vs. $14.33B debt (net ~$12.6B) ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-First-Quarter-2025-Results/default.aspx#:~:text=As%20of%20March%2031%2C%202025%2C,Cash%20Flow%20was%20%24426%20million)); trailing leverage ~3.4× EBITDA. No dividend is paid (all cash returned via buybacks). 2022–24 free cash flow was strong ($1.59B, $1.50B, $2.11B) ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2023/IQVIA-Reports-Fourth-Quarter-and-Full-Year-2022-Results-Issues-Full-Year-2023-Guidance/default.aspx#:~:text=quarter%20of%202022%2C%20Operating%20Cash,Cash%20Flow%20was%20%241%2C586%20million)) ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-Fourth-Quarter-and-Full-Year-2024-Results-Reaffirms-Full-Year-2025-Guidance/default.aspx#:~:text=match%20at%20L524%20Free%20Cash,OF%20GROSS%20AND%20NET%20LEVERAGE)), funding repurchases. Given the debt load, we rate Financial Strength **Medium** (ample liquidity but elevated leverage).  

**Management:** CEO Ari Bousbib (IQVIA since 2016, ex-Quintiles) and CFO Ron Bruehlman (joined 2022) have stable tenures. They provide clear guideposts (booking/ backlog trends, margin targets) and have been transparent with quarterly guidance.  

**Risks:** • **Biotech/Pharma spending:** Continued high interest rates strain funding for R&D—IQVIA noted some customer delays in starting new trials ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-First-Quarter-2025-Results/default.aspx#:~:text=,looking%20indicators%20such%20as%20qualified)). A sharper downturn in drug development budgets could slow R&DS growth. • **Macroeconomic and FX:** Currency swings (favorable in Q1 2025) can materially affect results. • **Competitive:** CRO market share battles (e.g. by Danaher/Thermo services) could pressure pricing. • **Regulatory/data:** Evolving data privacy laws or industry regulations could impact IQVIA’s data analytics services (Assumption). • **Execution:** Missed backlog conversion or booking targets would hurt confidence.  

**Company Description:** IQVIA (NYSE:IQV) is a global provider of outsourced clinical research, commercial insights and healthcare analytics to pharmaceutical, biotech, and medical device companies ([www.iqvia.com](https://www.iqvia.com/newsroom/2025/05/iqvia-reports-first-quarter-2025-results#:~:text=RESEARCH%20TRIANGLE%20PARK%2C%20N.C.,reported%20financial%20results%20for%20the)). Its offerings include clinical trial management, contract sales, real-world data products and AI-enabled analytics. The company operates in 100+ countries with ~89,000 employees ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-First-Quarter-2025-Results/default.aspx#:~:text=safety%2C%20and%20delivering%20AI%20to,outcomes%20and%20population%20health%20worldwide)), leveraging one of the world’s largest healthcare data platforms (IQVIA Connected Intelligence™) to help clients accelerate drug development and commercialization.  

**Valuation:** Our $240 target uses a ~20× FY2025 adj. EPS multiple (~5% premium to historical average and near the midpoint of peer multiples).  This implies ~20% upside from current levels. By comparison, Danaher trades at ~27× ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/LH/labcorp/pe-ratio#:~:text=Danaher%20%28DHR%29%20%20%20,28.40)) and ICON at ~13× ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/LH/labcorp/pe-ratio#:~:text=ICON%20%28ICLR%29%20%20%20,34.15)) forward EPS.  The target multiple is above IQVIA’s 5–year median (~19×) but below high-growth peers.  Upside drivers include faster-than-expected pharma R&D recovery or new product wins; downside risks include persistent cuts in clinical budgets. A rating upgrade to BUY-on-strength would require sustained outperformance or higher booking growth; a downgrade would follow clear inflection in CRO spending or guidance misses.  

**Ratings Reference:** **BUY:** Expected to outperform broad market on a risk-adjusted basis (12-mth horizon). **HOLD:** Expected to match market returns. **SELL:** Expected to underperform. *(Long-term (5-year) outlook vs. peers shown as `%` above; sector stance is Market-weight.)*  

**Methodology & Disclaimers:** This analysis combines top-down industry and economic outlook (global biotech R&D trends, healthcare spending growth, interest-rate environment) with bottom-up fundamentals (IQVIA’s segment growth, margins, cash flows, balance sheet, and management quality). Valuation is based on peer-group multiples and discounted cash flow considerations.  This report is for informational purposes only and not investment advice; readers should consider their own objectives and consult a professional.  

**Sources:** IQVIA earnings releases and SEC filings ([www.iqvia.com](https://www.iqvia.com/newsroom/2025/05/iqvia-reports-first-quarter-2025-results#:~:text=Revenue%20for%20the%20first%20quarter,1%20percent%20at%20constant%20currency)) ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-First-Quarter-2025-Results/default.aspx#:~:text=As%20of%20March%2031%2C%202025%2C,Cash%20Flow%20was%20%24426%20million)); management commentary ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-First-Quarter-2025-Results/default.aspx#:~:text=,looking%20indicators%20such%20as%20qualified)); company investor materials ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-First-Quarter-2025-Results/default.aspx#:~:text=Connected%20Intelligence%E2%84%A2%20to%20deliver%20actionable,powered%20capabilities%20built)) ([www.iqvia.com](https://www.iqvia.com/newsroom/2025/05/iqvia-reports-first-quarter-2025-results#:~:text=%2A%20Raised%20full,exchange%20rates%3B%20reaffirmed%20profit%20guidance)); industry publications ([www.worldpharmatoday.com](https://www.worldpharmatoday.com/news/promising-future-for-the-global-cro-market-with-8-4-cagr/#:~:text=As%20per%20insights%2C%20the%20global,its%20growth%20in%20the%20future)); Reuters news ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/iqvia-raises-annual-profit-forecast-improving-demand-analytics-services-2024-07-22/#:~:text=in%20the%20second%20quarter,affecting%20biotech%20funding%2C%20the%20outlook)). (Historical financials and ratios from company reports.)